VEGFA and neoplasm: On the basis of the proposed concept of precision medicine, targeted drugs developed based on tumour characteristics have emerged in an endless stream, and among these drugs, antiangiogenic agents mainly target VEGF, thereby inhibiting a series of pathophysiological processes regulated by VEGF and benefiting patients with tumours such as ovarian or breast cancer (163, 164).